The firm is a government-backed venture capital firm headquartered in Asia. The firm manages a large growth-stage investment fund while increasingly expanding its focus to earlier-stage innovation with global potential. Typical initial investments are approximately $5M, with the flexibility to deploy substantially larger amounts depending on the opportunity. Although the firm has historically invested primarily in domestic growth-stage companies, it is actively seeking early-stage opportunities globally.
The firm invests across therapeutics, digital therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across all disease areas. The firm generally prefers programs that have entered early clinical development and is less inclined to invest in preclinical-stage assets. Beyond therapeutics, the firm remains open to innovative healthcare technologies with strong commercial and global growth potential. From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm is open to acting as either a lead investor or co-investor and typically seeks board representation when serving as the lead investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment